Relative Dose Intensity: Improving Cancer Treatment and Outcomes
Purpose/Objectives: To determine the incidence of and reasons for chemotherapy dose delays or reductions.
Design: A performance improvement initiative formed the basis for a prospective nursing research study.
Setting: A single institution in western Pennsylvania.
Sample: 204 patients scheduled for nonmyeloablative chemotherapy.
Methods: Data collection forms were completed by RNs and evaluated by an interdisciplinary team.
Main Research Variables: Rates of nonadherence to chemotherapy schedule or dosing and associated reasons.
Findings: The performance improvement initiative revealed evidence of nonadherence to chemotherapy schedule or dosing when patient-requested cancellations and physician-ordered dose delays and reductions were left unchallenged and medical and nursing staffs had limited knowledge of or interest in relative dose intensity. The ensuing nursing research study found that less than 51% and 78% of patients adhered to their schedule and dosage, respectively. Nonadherence primarily was attributed to canceled visits, suboptimal or nonuse of hematopoietic growth factors, and routine dose reductions. Subsequent educational initiatives targeting the interdisciplinary team and patients and their families focused on the importance of keeping scheduled visits and preventing versus managing pancytopenia. Adopting a telephone referral procedure and distributing a patient education sheet reduced patient cancellations by 50%. Various reasons for dose delays and reductions have surfaced, many of which are modifiable with educational efforts.
Conclusions: A knowledge deficit was found among patients and healthcare providers regarding the importance of adhering to chemotherapy orders.
Implications for Nursing: Evaluating patterns of chemotherapy administration and educating patients, nurses, and physicians will have an impact on relative dose intensity, potentially improving treatment outcomes.
Jump to a section
References
Abels, R.I. (1992). Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematologica, 87(Suppl. 1), 4-11.
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. New England Journal of Medicine, 332, 901-906.
Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood, W.C., Weiss, R.B., et al. (1998). Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Journal of the National Cancer Institute, 90, 1205-1211.
Cairo, M.S. (2000). Dose reductions and delays: Limitations of myelosuppressive chemotherapy. Oncology, 14(9, Suppl. 8), 21-31.
Citron, M.L., Berry, D.A., Cirrincione, C., Hudis, C., Winer, E.P., Gradishar. W.J., et al. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Oncology, 21, 1431-1439.
Cunningham, R.S. (2003). Anemia in the oncology patient: Cognitive function and cancer. Cancer Nursing, 26(6, Suppl.), 38S-42S.
Desoize, B., & Madoulet, C. (2002). Particular aspects of platinum compounds used at present in cancer treatment. Critical Reviews in Oncology and Hematology, 42, 317-325.
Ellis, M., Zwaan, R, Hedstrom, U., Poynton, C., Kristensen, J., Jumaa, P., et al. (2003). Recombinant human interleukin 11 and bacterial infection in patients with [correction of] haematological malignant disease undergoing chemotherapy: A double-blind placebo-controlled randomised trial. Lancet, 361, 275-280.
Epelbaum, R., Haim, N., Ben-Shahar, M., Ron, Y., & Cohen, Y. (1988). Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Israel Journal of Medical Sciences, 24, 533-538.
Frasci, G. (2002). Treatment of breast cancer with chemotherapy in combination with filgrastim: Approaches to improving therapeutic outcome. Drugs, 62(Suppl. 1), 17-31.
Frei, E., III, & Canellos, G.P. (1980). Dose: A critical factor in cancer chemotherapy. American Journal of Medicine, 69, 585-594.
Groopman, J.E., & Itri, L.M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91, 1616-1634.
Harrison, L.B., Shasha, D., & Homel, P. (2002). Prevalence of anemia in cancer patients undergoing radiotherapy: Prognostic significance and treatment. Oncology, 63(Suppl. 2), 11-18.
Isaacs, C., Robert, N.J., Bailey, F.A., Schuster, M.W, Overmoyer, B., Graham, M., et al. (1997). Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. Journal of Clinical Oncology, 15, 3368-3377.
Kwak, L.W., Halpern, J., Olshen, R.A., & Homing, S.J. (1990). Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. Journal of Clinical Oncology, 8, 963-977.
Nirenberg, A. (2003). Managing hematologic toxicities: Novel therapies. Cancer Nursing, 26(6, Suppl.), 32S-37S.
Norton, L. (1988). A Gompertzian model of human breast cancer growth. Cancer Research, 48(24, Pt. 1), 7067-7071.
Ozer, H., Armitage, J.O., Bennett, C.L., Crawford, J., Demetri, G.D., Pizzo, P.A., et al. (2000). 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. Journal of Clinical Oncology, 18, 3558-3585.
Pettengell, R., Gurney, H., Radford, J.A., Deakin, D.P., James, R., Wilkinson, P.M., et al. (1992). Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood, 80, 1430-1436.
Rodgers, S.M., Cella, D., Chanan-Khan, A., Cleeland, C., Coccia, P.P., Demetri, G.D., et al. (2005). Cancer and treatment-related anemia. Retrieved December 1, 2003, from http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf
Schiffer, C.A., Anderson, K.C., Bennett, C.L., Bernstein, S., Elting, L.S., Goldsmith, M., et al. (2001). Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology, 19, 1519-1538.
Tepler, I., Elias, L., Smith, J.W., II, Hussein, M., Rosen, G., Chang, A.Y., et al. (1996). A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood, 87, 3607-3614.